Hua Medicine Annual Report 2025: In-Depth Analysis and Key Investor Takeaways

1. Financial Highlights: Major Turnaround to Profitability

• Revenue Surge: The Group recorded a significant increase in revenue, reaching RMB492.9 million in 2025, compared to RMB255.9 million in 2024. This nearly doubled revenue is primarily attributed to the growing sales of the Company’s flagship product, dorzagliatin (HuaTangNing®), a first-in-class oral glucokinase activator for Type 2 diabetes.
• Gross Profit: Gross profit soared to RMB280.4 million, up from RMB124.7 million, reflecting strong operating leverage as the product scales in the market.
• Net Profit: Most notably, Hua Medicine swung to a net profit of RMB1,106.4 million from a loss of RMB250.1 million the previous year. The dramatic improvement was largely driven by a one-off other income item of RMB1,263.9 million, which is likely non-recurring and warrants investor attention.
• Earnings Per Share (EPS): Basic EPS turned positive at RMB1.12 (2024: -RMB0.25); diluted EPS was RMB1.10 (2024: -RMB0.25).
• Research and Development (R&D) Expenses: R&D spending decreased to RMB145.3 million from RMB215.1 million, indicating a potential shift from heavy development to commercialization focus.
• Administrative and Selling Expenses: Administrative expenses were stable at RMB114.5 million, while selling and distribution expenses rose slightly to RMB165.5 million, reflecting increased commercial activities.
• Dividend: No dividend was declared for 2025, maintaining the Company’s policy to reinvest profits into the business.

2. Balance Sheet Strength and Ratios

• Liquidity: The current ratio improved significantly to 6.2 (2024: 4.0), and the quick ratio to 5.6 (2024: 3.7), mainly due to reduced short-term borrowings and a robust cash position.
• Gearing Ratio: The Company’s gearing ratio is now at 30.0%, down from a negative equity position last year— a notable improvement and a reflection of strengthened financial health.
• Cash and Cash Equivalents: Despite the profit, cash and cash equivalents fell slightly to RMB1,092.3 million (2024: RMB1,139.8 million) due to ongoing investments and debt repayments.
• Indebtedness: Total borrowings and lease liabilities remained stable at RMB301.7 million, with a shift towards longer-term debt (non-current portion increased).

3. Operational and Strategic Developments

• Product Approval and Sales: Dorzagliatin continues to be the Group’s core revenue driver after its regulatory approval in China in October 2022. Commercialization under the tradename HuaTangNing® accelerated in 2025.
• Share Incentive Schemes: The Company continues to incentivize management and staff through substantial share option grants. In 2025, 29.7 million shares (3.0% of weighted average shares) were issued under share schemes, aligning employees’ interests with shareholders.
• Connected Transactions: No connected or continuing connected transactions requiring disclosure under the Listing Rules were entered into in 2025, reducing governance risk.
• Corporate Governance: The Company has complied with the Corporate Governance Code, with plans to enhance board diversity by appointing a female director to the nomination committee by mid-2026.

4. Risks and Sensitivities

• Foreign Exchange Risk: The Group experienced foreign exchange losses of RMB4.5 million in 2025 (2024: gain of RMB2.0 million), primarily due to the depreciation of USD and HKD against RMB. The Company remains exposed to currency fluctuations as a large portion of its cash is held in foreign currencies.
• Interest Rate Risk: With exposure to both fixed and variable-rate debt, a 50 basis point change in interest rates would impact profit by approximately RMB1.07 million.
• Customer Concentration: 34.99% of receivables are due from the largest customer, and 75.38% from the top five, highlighting a significant customer concentration risk.
• Dependence on Third Parties: The Company’s reliance on third-party CMOs for commercial production remains a key operational risk.

5. Shareholder and Governance Matters

• No Dividend Recommendation: The Board did not recommend a final dividend for 2025, consistent with 2024, as profits are being retained for growth and expansion.
• Share Capital: As of December 31, 2025, issued share capital increased to 1,056,605,016 shares following the exercise of share options.
• Shareholder Structure: Substantial shareholders include ARCH Venture Fund VII, L.P. (11.85%), Venrock Associates V, L.P. (9.80%), and several trusts and nominee entities, with no single controlling shareholder.
• No Treasury Shares: The Company holds no treasury shares.
• Public Float: Maintained as required by Hong Kong Listing Rules.

6. Other Noteworthy Items

• Audit Opinion: The audit was unqualified (“true and fair view”), with Deloitte Touche Tohmatsu re-appointed as auditor.
• Future Standards: The Company is preparing for new IFRS standards which may affect the presentation of future financial statements.
• Events After Reporting Period: No significant subsequent events requiring disclosure or adjustment were noted.

7. Potential Share Price Movers & Investor Considerations

• Positive Drivers: The substantial swing to profitability, strong revenue growth, and improved balance sheet are likely to be viewed favorably by investors.
• One-Off Income: The large “Other Income” item (RMB1.26 billion) that drove profits in 2025 appears to be non-recurring. Investors should scrutinize this for sustainability of profit growth.
• Product Commercialization: Continued success and potential expansion of dorzagliatin sales, regulatory developments, and possible international commercialization remain key catalysts for the stock.
• Risks: High customer concentration, foreign exchange volatility, and reliance on third parties for manufacturing require monitoring.
• Corporate Governance: Plans to enhance diversity and compliance with the latest corporate governance standards may support investor confidence.

Conclusion

Hua Medicine’s 2025 annual report marks a critical inflection point for the company, with a dramatic move to profitability and robust sales growth of its first-in-class diabetes drug. However, given the non-recurring nature of the main profit driver and ongoing operational risks, investors should closely monitor future earnings quality and the sustainability of growth.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions. The financial data and analysis above are based on Hua Medicine’s 2025 published annual report and may be subject to updates or revisions.

View HUA MEDICINE-B Historical chart here